Research programme: induced pluripotent stem cells derived macrophages - Factor Bioscience
Alternative Names: mRNA-based iPS cell-derived macrophages - Factor BioscienceLatest Information Update: 24 Jun 2022
At a glance
- Originator Factor Bioscience
- Class Antineoplastics; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 May 2022 Induced pluripotent stem cells derived macrophages - Factor Bioscience is available for licensing as of 16 May 2022. https://factor.bio/partners/
- 16 May 2022 Preclinical trials in Solid tumours in USA (Parenteral) as of May 2022
- 16 May 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the American Society of Gene & Cell Therapy (ASGCT-2022) 25th Annual Meeting